A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.

A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Abstract Text:

H Choy,R F De Vore,K R Hande,L L Porter,P A Rosenblatt,B Slovis,K Laporte,Y Shyr,D H Johnson,

Docetaxel has demonstrated activity as a radiosensitizer in numerous preclinical studies, probably due to its role as a cell cycle synchronizer for the G2/M radiosensitive phase of the cell cycle. We conducted a phase I trial to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLT) of docetaxel with concurrent thoracic radiation therapy (TRT) to patients with unresectable stage III non small-cell lung cancer (NSCLC). Fifteen patients were entered into this study. Docetaxel was administered as a 1-hour intravenous (I.V.) infusion, repeated every week for 6 weeks with starting dose of 20 mg/m2. Doses were escalated in 10 mg/m2 increments in successive cohorts of three new patients, if tolerated. Unacceptable toxicity was defined as grade = 3 nonhematologic or hematologic toxicity according to Eastern Cooperative Oncology Group (ECOG) toxicity criteria. TRT was administered to the primary tumor and regional lymph nodes (40 Gy) followed by a boost to the tumor (20 Gy). At the first dose level (20 mg/m2/week), one pa-tient developed grade 4 hyperglycemia and accrual was expanded to five patients. At the second level (30 mg/m2/week), two out of six patients developed grade 3 esophagitis. At the third level (40 mg/m2/week), two out of four patients developed grade 3 esophagitis and one patient developed grade 3 pulmonary tox-icity. The weekly docetaxel MTD with concurrent radiation therapy (RT) was found to be 30 mg/m2. The DLT was esophagitis and pulmonary toxicity. Other toxicities encountered included skin reaction, nausea and vomiting, as well as diarrhea. Additionally, there were no treatment-related mortalities or late-occurring toxicities. Esophagitis was the principal DLT of concurrent weekly docetaxel and thoracic radiation in the outpatient setting. The MTD of concurrent weekly docetaxel with TRT is 30 mg/m2 weekly for 6 weeks. This study is still open to accrual with weekly docetaxel and TRT in locally advanced NSCLC patients.

A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Publishing Authors By Initials

H Choy,RF De Vore,KR Hande,LL Porter,PA Rosenblatt,B Slovis,K Laporte,Y Shyr,DH Johnson,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical lung cancer

VOLUME: 1 Suppl 1

Page Numbers: S27-31

Journal Abbreviation:

ISSN: 1525-7304

DAY: 16

MONTH: Apr

YEAR: 2000

A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100893225

A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.

AFFILIATION: Vanderbilt University Medical School, Nashville, TN, Vanderbilt Cancer Center, Nashville, TN; e-mail: Hak. Choy@mcmail.vanderbilt.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Lung Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network VCCAN Trial Related Publications

• A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.
• A method for one-step freezing of mouse embryos.
• Active immunization of boars against gonadotrop in releasing hormone. I. Effects on reproductive parameters.
• Active immunization of boars against gonadotropin releasing hormone. II. Effects on libido and response to testosterone propionate.
• An eight-position capillary sample spinning stage for the diffractometer at BL20B at the Photon Factory.
• An extract of the mushroom Agaricus blazei Murill protects against lethal septicemia in a mouse model of fecal peritonitis.
• Cardiac hypertrophy in infancy.
• Effect of castration on plasma luteinizing hormone in postpubertal boars.
• Effects of postparturient uterine lavage on uterine involution in the mare.
• Effects of pretreatment with adrenocorticotropin on endocrine and behavioral responses of bulls to sexual activity.
• Effects of zeranol upon bovine testicular function.
• Embryo transfer tests for bovine syndactyly.
• Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model.
• Factors related to successful sperm microinjection of hamster eggs: The effect of sperm species, technical experience, needle dimensions, and incubation medium on egg viability and sperm decondensation following microinjection.
• Leading from the edge, and toward the light: some lessons on leadership from the business world.
• Progesterone profiles in postpartum Holstein dairy cows as an aid in the study of retained fetal membranes, pyometra and anestrus.
• Quantum-dot-based nanosensor for RRE IIB RNA-Rev peptide interaction assay.
• Relationship between serum luteinizing hormone and estradiol in prepubertal boars.
• Scrotal circumference does not accurately predict degree of germinal epithelial loss or semen quality in yearling Hereford and Simmental bulls.
• Single site electronic spectroscopy of free base octaethylporphyrin, octaethychlorin and their diacids in n-octane at 298K and 7K.
• Single site electronic spectroscopy of magnesium isobacteriochlorin in n-octane matrixes at 7 K.
• Skin and subcutaneous tissue in rhinoplasty.
• Techniques of Online Citation Verification in NLM Databases.
• Temporal relationships among peripheral blood concentrations of corticosteroids, luteinizing hormone and testosterone in bulls.
• Testing the adaptive value of circadian systems.
• The effect of co-treatment with recombinant bovine somatotrophin on plasma progesterone concentration and number of embryos collected from superovulated Holstein heifers.
• The effect of prostaglandin administration to Holstein-Friesian cows at Day 26 postpartum on clinical findings, and histological and bacteriological results of endometrial biopsies at Day 40.
• The recovery of ureaplasmas from bovine embryos following in vitro exposure and ten washes.
• The use of real-time ultrasound rectally for early pregnancy diagnosis in sheep.
• Variation in testosterone production among boards and its relationship to sexual interest and breeding performance.